ABSTRACT OBJECTIVE: To estimate the seroprevalence of SARS-CoV-2 in the state of Maranhão, Brazil. METHODS: A population-based household survey was performed, from July 27, 2020 to August 8, 2020. The estimates considered clustering, stratification and non-response. Qualitative detection of IgM and IgG antibodies was performed in a fully-automated Elecsys® Anti-SARS-CoV-2 electrochemiluminescence immunoassay on the Cobas® e601 analyzer (Roche Diagnostics). RESULTS: In total, 3,156 individuals were interviewed. Seroprevalence of total antibodies against SARS-CoV-2 was 40.4% (95%CI 35.6-45.3). Population adherence to non-pharmaceutical interventions was higher at the beginning of the pandemic than in the last month. SARS-CoV-2 infection rates were significantly lower among mask wearers and among those who maintained social and physical distancing in the last month compared to their counterparts. Among the infected, 26.0% were asymptomatic. The infection fatality rate (IFR) was 0.14%, higher for men and older adults. The IFR based on excess deaths was 0.28%. The ratio of estimated infections to reported cases was 22.2. CONCLUSIONS: To the best of our knowledge, the seroprevalence of SARS-CoV-2 estimated in this population-based survey is one of the highest reported. The local herd immunity threshold may have been reached or might be reached soon.

ABSTRACT OBJECTIVE: To estimate the seroprevalence of SARS-CoV-2 in the state of Maranhão, Brazil. METHODS: A population-based household survey was performed, from July 27, 2020 to August 8, 2020. The estimates considered clustering, stratification and non-response. Qualitative detection of IgM and IgG antibodies was performed in a fully-automated Elecsys® Anti-SARS-CoV-2 electrochemiluminescence immunoassay on the Cobas® e601 analyzer (Roche Diagnostics). RESULTS: In total, 3,156 individuals were interviewed. Seroprevalence of total antibodies against SARS-CoV-2 was 40.4% (95%CI 35.6-45.3). Population adherence to non-pharmaceutical interventions was higher at the beginning of the pandemic than in the last month. SARS-CoV-2 infection rates were significantly lower among mask wearers and among those who maintained social and physical distancing in the last month compared to their counterparts. Among the infected, 26.0% were asymptomatic. The infection fatality rate (IFR) was 0.14%, higher for men and older adults. The IFR based on excess deaths was 0.28%. The ratio of estimated infections to reported cases was 22.2. CONCLUSIONS: To the best of our knowledge, the seroprevalence of SARS-CoV-2 estimated in this population-based survey is one of the highest reported. The local herd immunity threshold may have been reached or might be reached soon.

BACKGROUND:Herpes zoster or, as it is commonly called, 'shingles' is a neurocutaneous disease characterised by the reactivation of varicella zoster virus (VZV), the virus that causes chickenpox, which is latent in the dorsal spinal ganglia when immunity to VZV declines. It is an extremely painful condition which can often last for many weeks or months, impairing the patient's quality of life. The natural aging process is associated with a reduction of cellular immunity which predisposes to herpes zoster. Vaccination with an attenuated form of VZV activates specific T cell production, therefore avoiding viral reactivation. A herpes zoster vaccine with an active virus has been approved for clinical use among older adults by the Food and Drug Administration and has been tested in large populations.OBJECTIVE:To evaluate the effectiveness and safety of vaccination for preventing herpes zoster in older adults.METHODSSearch methods: We searched the following sources for relevant studies: CENTRAL 2012, Issue 7, MEDLINE (1948 to July week 1, 2012), EMBASE (2010 to July 2012), LILACS (1982 to July 2012) and CINAHL (1981 to July 2012). We also reviewed reference lists of identified trials and reviews for additional studies.Selection criteria: Randomised controlled trials (RCTs) or quasi-RCTs comparing zoster vaccine with placebo or no vaccine, to prevent herpes zoster in older adults (mean age > 60 years).Data collection and analysis: Two review authors independently collected and analysed data using a data extraction form. They also carried out an assessment of risk of bias.MAIN RESULTS:We identified eight RCTs with a total of 52,269 participants. Three studies were classified at low risk of bias. The main outcomes on effectiveness and safety were extracted from one clinical trial with a low risk of bias. Four studies compared zoster vaccine versus placebo; one study compared high-potency zoster vaccine versus low-potency zoster vaccine; one study compared refrigerated zoster vaccine versus frozen zoster vaccine; one study compared live zoster vaccine versus inactivated zoster vaccine and one study compared zoster vaccine versus pneumococcal polysaccharide vaccine (pneumo 23).Confirmed cases of herpes zoster were less frequent in patients who received the vaccine than in those who received a placebo: risk ratio (RR) 0.49 (95% confidence interval (CI) 0.43 to 0.56), with a risk difference (RD) of 2%, and number needed to treat to benefit (NNTB) of 50. Analyses according to age groups indicated a greater benefit in participants aged 60 to 69 years, RR 0.36 (95% CI 0.30 to 0.45) and in participants aged 70 years and over, RR 0.63 (95% CI 0.53 to 0.75). Vaccine-related systemic adverse effects were more frequent in the vaccinated group (RR 1.29, 95% CI 1.05 to 1.57, number needed to treat to harm (NNTH) = 100). The pooled data risk ratio for adverse effects for participants with one or more inoculation site adverse effect was RR 4.51 (95% CI 2.35 to 8.68), and the NNTH was 2.8 (95% CI 2.3 to 3.4). Side effects were more frequent in younger (60 to 69 years) than in older (70 years and over) participants.AUTHORS' CONCLUSIONS:Herpes zoster vaccine is effective in preventing herpes zoster disease. Although vaccine benefits are larger in the younger age group (60 to 69 years), this is also the age group with more adverse events. In general, zoster vaccine is well tolerated; it produces few systemic adverse events and injection site adverse effects of mild to moderate intensity.

CONTEXTO E OBJETIVO: De acordo com alguns estudos de coorte, a prevalência da esquizofrenia refratária (ER) está entre 20-40%. Nosso objetivo foi avaliar a efetividade e segurança de aripiprazol, paliperidona, quetiapina e risperidona no tratamento da esquizofrenia refratária. MÉTODOS: Avaliação crítica das revisões Cochrane publicadas na Biblioteca Cochrane e complementação com referências de ensaios clínicos randomizados (ECRs) mais atualizados sobre ER. As seguintes bases de dados foram pesquisadas: Medline (Medical Literature Analysis and Retrieval System Online) (1966-2009), Ensaios Controlados da Colaboração Cochrane (2009, edição 2), Embase (Excerpta Database) (1980-2009), Lilacs (Literatura Latino-Americana e do Caribe em Ciências da Saúde) (1982-2009). Não houve restrição a idiomas. Ensaios clínicos randomizados, revisões sistemáticas e metanálises que avaliaram antipsicóticos atípicos no tratamento da esquizofrenia refratária foram incluídos. RESULTADOS: Sete revisões sistemáticas Cochrane e 10 ECRs complementares foram incluídos nessa revisão. No geral os dados demonstram pequenas diferenças entre os antipsicóticos atípicos avaliados e os típicos na melhora dos sintomas da doença, apesar da melhor adesão ao tratamento com os atípicos. A risperidona foi avaliada especificamente em pacientes com esquizofrenia refratária em uma das revisões sistemáticas incluídas, a qual demonstrou desfechos favoráveis, porém não definitivos quando comparada a drogas também com eficácia comprovada como amisulprida, clozapina e olanzapina. CONCLUSÕES: Os dados reforçam a dificuldade de tratar esses pacientes, com elevadas taxas de desistência do tratamento e padrões de melhora modestos nas avaliações de eficácia. Os antipsicóticos atípicos têm vantagens sobre os típicos principalmente pelo melhor perfil de segurança, o que leva a melhor adesão ao tratamento. A associação de antipsicóticos também pode ser uma opção em alguns pacientes refratários ao tratamento.

CONTEXT AND OBJECTIVE: According to some cohort studies, the prevalence of refractory schizophrenia (RS) is 20-40%. Our aim was to evaluate the effectiveness and safety of aripiprazole, paliperidone, quetiapine and risperidone for treating RS. METHODS: This was a critical appraisal of Cochrane reviews published in the Cochrane Library, supplemented with reference to more recent randomized controlled trials (RCTs) on RS. The following databases were searched: Medical Literature Analysis and Retrieval System Online (Medline) (1966-2009), Controlled Trials of the Cochrane Collaboration (2009, Issue 2), Embase (Excerpta Medica) (1980-2009), Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs) (1982-2009). There was no language restriction. Randomized controlled trials, systematic reviews and meta-analyses evaluating atypical antipsychotics for treating RS were included. RESULTS: Seven Cochrane systematic reviews and 10 additional RCTs were included in this review. The data generally showed minor differences between the atypical antipsychotics evaluated and typical antipsychotics, regarding improvement in disease symptoms, despite better adherence to treatment with atypical antipsychotics. Risperidone was specifically evaluated in patients with RS in one of the systematic reviews included, with favorable outcomes, but without definitive superiority compared with other drugs of proven efficacy, like amisulpride, clozapine and olanzapine. CONCLUSIONS: The findings underscore the difficulty in treating these patients, with high dropout rates and treatment patterns of modest improvement in assessments of effectiveness. Atypical antipsychotics have advantages over typical antipsychotics mainly through their better safety profile, which leads to better adherence to treatment. A combination of antipsychotics may also be an option for some refractory patients.

CONTEXTO E OBJETIVO: Perda auditiva induzida por ruído pode apenas ser prevenida eliminando ou diminuindo os níveis de exposição sonora. Quando a fonte do ruído não pode ser eliminada, trabalhadores devem utilizar os equipamentos de proteção auditiva. O objetivo foi sumarizar as evidências sobre efetividade das intervenções para aumentar o uso de protetores auriculares entre trabalhadores expostos a ruídos. ESTRATÉGIA DE BUSCA: Estudos randomizados foram identificados por busca eletrônica na literatura médica até 2005. Os dados foram checados duplamente e inseridos no software Review Manager software, versão 4.2.5. RESULTADO PRINCIPAL: Dois estudos foram encontrados. Uma intervenção padronizada por computador em relação ao risco de um trabalhador individual durou 30 minutos e não foi mais efetiva do que um vídeo fornecendo informações gerais entre os trabalhadores. Um segundo ensaio clínico randomizado avaliou os efeitos de um programa de prevenção auditiva de quatro anos em uma escola onde jovens trabalhavam nas fazendas de seus pais. O grupo de intervenção foi duas vezes mais provável de usar algum tipo de protetor auricular do que o grupo controle, que recebeu mínima intervenção. CONCLUSÃO DOS REVISORES: Limitada evidência não demonstrou quando as intervenções padronizadas são mais ou menos efetivas do que intervenções gerais em trabalhadores, 80% deles já utilizavam o protetor auricular. Intervenções longas em escolas podem aumentar substancialmente o uso de protetores auriculares. Melhores intervenções para aumentar o uso de Equipamentos de Proteção Individual (EPIs) devem ser desenvolvidas e avaliadas com intuito de aumentar a prevenção de perda auditiva induzida por ruído em trabalhadores.

CONTEXT AND OBJECTIVE: Noise-induced hearing loss can only be prevented by eliminating or lowering noise exposure levels. When the source of the noise cannot be eliminated, workers have to rely on hearing protection equipment. The aim here was to summarize the evidence for the effectiveness of interventions to enhance the wearing of hearing protection among workers exposed to noise in the workplace. DATA SOURCE: Studies with random assignment were identified by an electronic search of the medical literature up to 2005. Data were double-entered into the Review Manager software, version 4.2.5. DATA SYNTHESIS: Two studies were found. A computer-based intervention tailored to individual workers’ risks and lasting 30 minutes was not found to be more effective than a video providing general information for workers. A second randomized controlled trial evaluated the effect of a four-year school-based hearing loss prevention program among schoolchildren working on their parents’ farms. The intervention group was twice as likely to wear some kind of hearing protection as was the control group (which received only minimal intervention). REVIEWERS’ CONCLUSIONS: The limited evidence does not show whether tailored interventions are more or less effective than general interventions among workers, 80% of whom already use hearing protection. Long-lasting school-based interventions may increase the use of hearing protection substantially. Better interventions to enhance the use of hearing protection need to be developed and evaluated in order to increase the prevention of noise-induced hearing loss among workers.

OBJETIVOS: A Escala de Impressão Clínica Global - Esquizofrenia é um instrumento de aplicação simples e rápido, utilizado para avaliar a severidade de sintomas em pacientes com esquizofrenia. Pode ser aplicado em estudos naturalísticos e na prática clínica. O objetivo deste trabalho é estudar as propriedades psicométricas e validar a versão Brasileira da Escala de Impressão Clínica Global - Esquizofrenia em nosso meio. MÉTODO: Estudo transversal de validação da Escala de Impressão Clínica Global - Esquizofrenia, na versão em Português, em pacientes com esquizofrenia, hospitalizados e em tratamento ambulatorial (DSM-IV, ICD-10), selecionados em seis centros no Brasil. Validade concorrente e sensibilidade à mudança foram determinadas em comparação com a escala Positive and Negative Syndrome Scale, considerada padrão-ouro. Confiabilidade interavaliador foi determinada através de coeficientes de correlação intraclasse (ICC), calculados a partir das pontuações de dois avaliadores concomitantemente. RESULTADOS: Setenta pacientes hospitalizados e 70 em tratamento ambulatorial foram incluídos. Os coeficientes de correlação de Pearson entre Escala de Impressão Clínica Global - Esquizofrenia e Positive and Negative Syndrome Scale foram: pontuação total (0,79), sintomas positivos (r = 0,86), negativos (r = 0,79), depressivos (r = 0,66) e cognitivos (r = 0,75, todos com p < 0,01). A confiabilidade interavaliadores da Escala de Impressão Clínica Global - Esquizofrenia foi alta para sintomas positivos e pontuação total; e moderada para sintomas negativos, depressivos e cognitivos. A sensibilidade ao grau de mudança foi moderadamente e significativamente correlacionada entre as duas escalas (r = 0,73, p < 0,01). CONCLUSÕES: A Escala de Impressão Clínica Global - Esquizofrenia em Português é um instrumento de boa validade e confiabilidade na avaliação da evolução de pacientes com esquizofrenia no Brasil, tanto em tratamento ambulatorial como hospitalizados.

OBJECTIVES: The Clinical Global Impression - Schizophrenia Scale was designed to assess severity and treatment response in subjects with schizophrenia involved in naturalistic studies and daily clinical practice. The objective of this study is to validate the Portuguese version of the Clinical Global Impression - Schizophrenia Scale in Brazil by assessing its psychometric properties. METHOD: Cross-sectional validation study of the Portuguese version of the Clinical Global Impression - Schizophrenia Scale, tested in outpatients and inpatients with schizophrenia (DSM-IV, ICD-10) from 6 centers in Brazil. Concurrent validity and sensitivity to change were assessed by comparison with the Positive and Negative Syndrome Scale, which is considered the gold standard tool to evaluate patients with schizophrenia. Interrater reliability was evaluated by intraclass correlation coefficients (ICC) calculated based on the scoring of two concomitant raters. RESULTS: 70 inpatients and 70 outpatients were evaluated. Total Clinical Global Impression - Schizophrenia Scale and Positive and Negative Syndrome Scale scores were highly correlated (r = 0.79; p < 0.01). Positive (r = 0.86), negative (r = 0.79), depressive (r = 0.66) and cognitive (r = 0.75) symptoms subscale scores were also correlated between both scales (p < 0.01). Sensitivity to change was significantly correlated between the Clinical Global Impression - Schizophrenia Scale and Positive and Negative Syndrome Scale (r = 0.73; p < 0.01). Interrater reliability was substantial for positive symptoms and total scores of the Clinical Global Impression - Schizophrenia Scale (ICC = 0.81 and 0.73), and moderate for negative, depressive, and cognitive symptoms score (0.64, 0.67 and 0.63, respectively). CONCLUSIONS: The Brazilian version of the Clinical Global Impression - Schizophrenia Scale is a valid and reliable instrument for the assessment of severity and treatment response in schizophrenic inpatient and outpatients.

CONTEXTO: A educação médica continuada definida de forma genérica como todas as formas pelas quais os médicos aprendem após a sua formação, é um assunto de interesse tanto dos médicos como dos pacientes em geral. No Brasil, os tocoginecologistas não são obrigados a se submeter a exames periódicos para certificar sua competência e atualização profissional, o que torna a educação médica continuada sujeita à de consciência pessoal. OBJETIVOS: Avaliar o desempenho de um grupo de tocoginecologistas em um teste escrito com perguntas sobre obstetrícia baseada em evidências e determinar sua opinião e uso regular de revisões sistemáticas. TIPO DE ESTUDO: Prospectivo de coorte. LOCAL DO ESTUDO: Congresso Brasileiro de Obstetrícia e Ginecologia 2001, em São Paulo. MÉTODOS: 230 médicos participaram voluntariamente do estudo durante o Congresso. Todos preencheram um questionário escrito, anônimo, individual com sete perguntas de múltipla escolha sobre condutas obstétricas clínicas baseadas em evidência, uma pergunta sobre interpretação de um gráfico de metanálise e duas perguntas sobre opinião e uso de revisões sistemáticas. Foi calculada a porcentagem de acerto de todos os participantes nas perguntas de múltipla escolha. Os resultados foram também analisados conforme o tempo de formado, residência, pós-graduação e docência. RESULTADOS: A média geral foi 49,2 + 17,4. As notas tenderam a cair com o tempo decorrido desde a formatura. Os médicos formados nos últimos cinco anos tiveram notas maiores que aqueles formados há mais de 25 anos (52,2 versus 42,9). O desempenho não variou significativamente conforme ter ou não residência, pós-graduação ou ser docente. Enquanto 98,2% consideravam as revisões sistemáticas relevantes, apenas 54,9% apontou o uso regular dessa fonte de informação médica. DISCUSSÃO: A nota média dos participantes foi baixa, apesar de sua boa formação e qualificação. Apesar das limitações deste estudo, os resultados são preocupantes. Se médicos motivados que participavam de um congresso nacional tiveram notas tão baixas, podemos especular que os resultados seriam ainda piores entre outros colegas que não participam desses eventos. CONCLUSÃO: Esses achados sugerem que os tocoginecologistas brasileiros poderiam se beneficiar com educação médica continuada e levanta questões acerca das formas atuais de reciclagem médica.

CONTEXT: In Brazil, obstetricians and gynecologists are not required to submit to periodical evaluations to ascertain their professional competence in dealing with new concepts and therapies. OBJECTIVES: To evaluate the performance of a group of obstetricians and gynecologists on a written evidence-based obstetrics test and determine their opinions and use of systematic reviews. TYPE OF STUDY: Prospective cohort. SETTING: Brazilian Obstetrics and Gynecology Congress 2001. METHODS: 230 doctors agreed to participate in the study during a national obstetrics and gynecology congress. Participants took an individual anonymous written multiple-choice test with seven questions on clinical obstetrics, one question on the interpretation of a meta-analysis graph and two questions on their opinions and actual use of systematic reviews. Scores were analyzed and compared after grouping the participants according to year of graduation, residence training, doctoral program and faculty status. RESULTS: The general average score was 49.2 ± 17.4. The scores tended to decline as the years since graduation advanced. Doctors who graduated in the last five years had higher scores than those who graduated over 25 years ago (52.2 versus 42.9). The performance did not vary according to medical residence, postgraduate program or teaching status. While 98.2% considered systematic reviews relevant, only 54.9% said that they routinely used this source of information. DISCUSSION: The participants' average score was low, even though they were highly qualified and trained. Despite the limitations of the study, the results are worrisome. If motivated physicians participating in a national congress obtained such low scores, we can speculate that the results might be even worse among other doctors that do not attend these events. CONCLUSIONS: These findings suggest that Brazilian obstetricians and gynecologists could benefit from continuing medical education and raise questions about the recycling methods currently available.

As intervenções usadas no manejo do transtorno do estresse pós-traumático (TEPT) focalizam-se em: (1) prevenção do desenvolvimento da doença após um evento traumático, (2) tratamento do quadro já estabelecido e (3) manutenção do funcionamento e da qualidade de vida em longo prazo. Uma variedade de tratamentos psicoterápicos e farmacológicos tem sido proposta para o tratamentos do TEPT. Entretanto, nem todas as modalidades de tratamento apresentam comprovação científica. No presente artigo, os autores apresentam as modalidades de tratamentos do TEPT amparadas em evidências e discutem sua aplicabilidade e limitações.

The interventions used in the clinical management of posttraumatic stress disorder (PTSD) focus on: 1. Prevention of the development of the disorder, after a traumatic event 2. Treatment of the disorder, once it is already established, 3. Maintenance of long term functioning and quality of life. A variety of psychotherapies and pharmacological treatments have been proposed as therapeutic options in the treatment of PTSD. However, many of these treatment modalities lack scientific background. In this article authors present the treatment modalities of PTSD which are supported by scientific evidence and discuss its applications and drawbacks.